The global market for Antimicrobial Susceptibility Testing was valued at US$3.7 Billion in 2024 and is projected to reach US$4.6 Billion by 2030, growing at a CAGR of 3.4% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Antimicrobial Susceptibility Testing market.
The importance of AST has increased with the rise of antibiotic-resistant bacteria, which pose a significant public health threat. Accurate and timely susceptibility testing helps in the stewardship of existing antibiotics by ensuring their appropriate use, thereby slowing the spread of resistance. Advances in AST technology have improved the speed and accuracy of results. Automated systems and molecular methods, such as PCR and next-generation sequencing, allow for rapid detection of resistance genes and provide more detailed information about bacterial pathogens. These technological advancements have made AST more efficient, enabling faster clinical decision-making and better patient outcomes.
The growth in the antimicrobial susceptibility testing market is driven by several factors. The increasing prevalence of antibiotic-resistant infections is a primary driver, necessitating more frequent and comprehensive testing. Government initiatives and regulations aimed at controlling the spread of resistance and improving antibiotic use are also contributing to market growth. Additionally, the growing demand for rapid and accurate diagnostic tools in healthcare settings has spurred the adoption of advanced AST methods. The expansion of clinical laboratories and the rising investment in research and development further support the market. These factors, combined with the ongoing need for effective infection control measures, ensure a strong growth trajectory for the antimicrobial susceptibility testing market.
Global Antimicrobial Susceptibility Testing Market - Key Trends & Drivers Summarized
Antimicrobial Susceptibility Testing (AST) is an essential process in microbiology that determines the effectiveness of antibiotics against specific bacterial pathogens. This testing is critical for guiding appropriate antibiotic therapy, helping clinicians choose the most effective treatment for infections. AST is performed using various methods, including disk diffusion, broth microdilution, and automated systems. Each method involves exposing the bacteria to different concentrations of antibiotics and observing their growth patterns. The results indicate whether the bacteria are susceptible, intermediate, or resistant to the antibiotics tested, which is vital information for treating infections and combating antibiotic resistance.The importance of AST has increased with the rise of antibiotic-resistant bacteria, which pose a significant public health threat. Accurate and timely susceptibility testing helps in the stewardship of existing antibiotics by ensuring their appropriate use, thereby slowing the spread of resistance. Advances in AST technology have improved the speed and accuracy of results. Automated systems and molecular methods, such as PCR and next-generation sequencing, allow for rapid detection of resistance genes and provide more detailed information about bacterial pathogens. These technological advancements have made AST more efficient, enabling faster clinical decision-making and better patient outcomes.
The growth in the antimicrobial susceptibility testing market is driven by several factors. The increasing prevalence of antibiotic-resistant infections is a primary driver, necessitating more frequent and comprehensive testing. Government initiatives and regulations aimed at controlling the spread of resistance and improving antibiotic use are also contributing to market growth. Additionally, the growing demand for rapid and accurate diagnostic tools in healthcare settings has spurred the adoption of advanced AST methods. The expansion of clinical laboratories and the rising investment in research and development further support the market. These factors, combined with the ongoing need for effective infection control measures, ensure a strong growth trajectory for the antimicrobial susceptibility testing market.
Report Scope
The report analyzes the Antimicrobial Susceptibility Testing market, presented in terms of market value (USD). The analysis covers the key segments and geographic regions outlined below.- Segments: Product (Manual Products, Automated Laboratory Instruments, Culture & Growth Media, Consumables); Testing Type (Antibacterial, Antifungal, Antiparasitic, Other Testing Types).
- Geographic Regions/Countries: World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Manual Products segment, which is expected to reach US$1.5 Billion by 2030 with a CAGR of 3.6%. The Automated Laboratory Instruments segment is also set to grow at 3% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $996.1 Million in 2024, and China, forecasted to grow at an impressive 6.7% CAGR to reach $992.2 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Antimicrobial Susceptibility Testing Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Antimicrobial Susceptibility Testing Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Antimicrobial Susceptibility Testing Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Accelerate Diagnostics, Inc., Alifax S.r.l., Becton Dickinson, and Company, bioMérieux SA, Bio-Rad Laboratories, Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 52 companies featured in this Antimicrobial Susceptibility Testing market report include:
- Accelerate Diagnostics, Inc.
- Alifax S.r.l.
- Becton Dickinson, and Company
- bioMérieux SA
- Bio-Rad Laboratories, Inc.
- Biotron Limited
- Bruker Corp.
- Creative Diagnostics
- Danaher Corporation
- ELITech Group
- F. Hoffmann-La Roche AG
- HiMedia Laboratories Pvt. Ltd.
- Liofilchem S.r.l.
- Mast Group Ltd.
- Merck KGaA
- MP Biomedicals LLC
- Q-linea AB
- QuantaMatrix, Inc.
- Resistell AG
- Thermo Fisher Scientific, Inc.
This edition integrates the latest global trade and economic shifts into comprehensive market analysis. Key updates include:
- Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
- Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes historical analysis from 2015 to 2023.
- Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
- Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
- Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
- Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Accelerate Diagnostics, Inc.
- Alifax S.r.l.
- Becton Dickinson, and Company
- bioMérieux SA
- Bio-Rad Laboratories, Inc.
- Biotron Limited
- Bruker Corp.
- Creative Diagnostics
- Danaher Corporation
- ELITech Group
- F. Hoffmann-La Roche AG
- HiMedia Laboratories Pvt. Ltd.
- Liofilchem S.r.l.
- Mast Group Ltd.
- Merck KGaA
- MP Biomedicals LLC
- Q-linea AB
- QuantaMatrix, Inc.
- Resistell AG
- Thermo Fisher Scientific, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 382 |
| Published | October 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 3.7 Billion |
| Forecasted Market Value ( USD | $ 4.6 Billion |
| Compound Annual Growth Rate | 3.4% |
| Regions Covered | Global |
